KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Shares Issued (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Shares Issued data on record, last reported at -$218000.0 in Q3 2025.

  • For Q3 2025, Shares Issued fell 1776.92% year-over-year to -$218000.0; the TTM value through Sep 2025 reached $83000.0, up 388.24%, while the annual FY2024 figure was $118000.0, N/A changed from the prior year.
  • Shares Issued reached -$218000.0 in Q3 2025 per NKTR's latest filing, down from $218000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $30.0 million in Q1 2024 and bottomed at -$30.0 million in Q2 2024.
  • Average Shares Issued over 5 years is $2.3 million, with a median of $188000.0 recorded in 2022.
  • Peak YoY movement for Shares Issued: surged 561.11% in 2024, then plummeted 1776.92% in 2025.
  • A 5-year view of Shares Issued shows it stood at $1.8 million in 2021, then tumbled by 94.28% to $103000.0 in 2022, then crashed by 117.48% to -$18000.0 in 2023, then soared by 561.11% to $83000.0 in 2024, then crashed by 362.65% to -$218000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were -$218000.0 in Q3 2025, $218000.0 in Q2 2025, and $83000.0 in Q4 2024.